Oculis Acquires Worldwide Rights to Privosegtor, a Neuroprotective Drug Candidate for Optic Neuropathies

Oculis Holding AG has announced an agreement to acquire all worldwide development and commercial rights to Privosegtor from Accure Therapeutics. Privosegtor, a novel peptoid small-molecule, has received Breakthrough Therapy designation from the FDA and Priority Medicines (PRIME) designation from the EMA for optic neuritis, and is currently in registrational trials for optic neuropathies. This acquisition aims to strengthen Oculis' position in neuro-ophthalmology.